🔴 NeoGenomics is trading 7% down in pre-market after no clear company-specific catalyst was identified

NeoGenomics is trading 7.07% down at $15.25 after no clear company-specific catalyst was identified for August 25, 2026.

• Recent coverage highlights strong second-quarter results, including $201.66 million in revenue and raised full-year guidance.
• The broader market is firmer pre-market: S&P 500 up 0.36% and Nasdaq Composite up 0.75%.
• The decline may reflect stock-specific trading pressure or profit-taking, but the catalyst remains unclear.